1456. Environmental and Nasal Pathogen Surveillance in Seattle Area Homeless Shelters

Abstract Background The need for community surveillance of respiratory viruses in high-risk settings such as homeless shelters has been underscored by the COVID-19 pandemic. Here, we show that sampling high-touch surfaces is a low-cost, minimally intensive means virus surveillance. Methods Environmental samples were collected weekly from adult and family King County, WA November 2019 – April 2020. At times when residents present, 10cm2 area selected swabbed bioaerosol high-traffic areas. Surfaces included entrance restroom doorknobs, counters, unique to each shelter. Study staff mid-turbinate swabs shelter resident participants aged > 3 months with symptoms acute illness (ARI). All tested RT-PCR 27 viruses. From January 1, 2020 onward, also SARS-CoV-2. Results A total 788 environmental swabs, 1509 nasal 98 6 tested. Adenovirus (109 positive 13.8% swabs), rhinovirus (107, 13.6%) human bocavirus (62, 7.9%) most frequently detected surface swabs. Rhinovirus (160, 10.6%), coronaviruses (79, 5.24%) influenza B (43, 2.85%) found Of 9 surfaces, exterior bathroom doorknobs physical location highest number pathogens detected. SARS-CoV-2 was first on 3/20/20, 3/10/20. Bioaerosol low percentage relative Table 1Count period prevalence viral detection type, 18, - 10, 2020.Figure 1Number disaggregated type.Figure 2Bar graphs comparing pathogen swabs/bioaerosol epidemiologic week, 30, Conclusion Respiratory through similar ARI episodes study participants. presents plausible, invasive method both endemic emerging pathogens, evidenced during early stages Further research could focus public locations broader culturing these surfaces. Disclosures Michael J. Boeckh, MD PhD, Allovir: Advisor/Consultant|Amazon: Grant/Research Support|Ansun Biopharma: Support|EvrysBio: Advisor/Consultant|Gates Ventures: Support|Gilead Sciences: Advisor/Consultant|Gilead Support|GlaxoSmithKline: Advisor/Consultant|GlaxoSmithKline: Support|Helocyte: Advisor/Consultant|Janssen: Support|Kyorin Pharmaceuticals: Advisor/Consultant|Merck: Support|Moderna: Advisor/Consultant|Moderna: Support|Regeneron: Support|ReViral: Advisor/Consultant|Symbio: Advisor/Consultant|Takeda: Support|Vir Biotechnology: Advisor/Consultant|Vir Support Janet A. Englund, MD, AstraZeneca: Advisor/Consultant|AstraZeneca: Support|Meissa Vaccines: Support|Pfizer: Support|Sanofi Pasteur: Advisor/Consultant Helen Y. Chu, MPH, Cepheid: Reagents|Ellume: Support|Merck: Advisor/Consultant|Pfizer: Advisor/Consultant.